A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Arthritis Research and Therapy

Volumn 20, Issue 1, 2018, Pages

  Fleischmann, Roy M ^a   Alten, Rieke ^b   Pileckyte, Margarita ^c   Lobello, Kasia ^d   Hua, Steven Y ^d   Cronenberger, Carol ^d   Alvarez, Daniel ^d   Bock, Amy E ^d   Sewell, K Lea ^d  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^d PFIZER INC   (United States)

Author keywords

Adalimumab; Biosimilar; Comparative clinical study; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; C REACTIVE PROTEIN; FOLINIC ACID; METHOTREXATE; PF 06410293; PREDNISONE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INTENTION TO TREAT ANALYSIS; LIVER DISEASE; LOW DRUG DOSE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OPEN STUDY; OPPORTUNISTIC INFECTION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH DISEASE; AGED;

ADALIMUMAB; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 85051718577     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-018-1676-y     Document Type: Article

References (20)

1. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33:679-707. https://doi.org/10.1016/j.clinthera.2011.05.044.
2. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45. https://doi.org/10.1002/art.10697.
3. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11. https://doi.org/10.1002/art.20217.
4. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. https://doi.org/10.1002/art.21519.
5. European Medicines Agency. HUMIRA (adalimumab) summary of product characteristics. 2017 (last update: 10 May 2017). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed 19 Feb. 2018.
6. Abbott Laboratories. HUMIRA (adalimumab) package insert. 2003 (last update: 26 September 2003). https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/adalabb123102LB.htm. Accessed 19 Feb. 2018.
7. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015 (last update: April 2015). https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed 19 Feb. 2018.
8. European Medicines Agency. Guideline on similar biological medicinal products. 2014 (last update: July 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 19 Feb. 2018.
9. QuintilesIMS. The impact of biosimilar competition in Europe. 2017 (last update: May 2017). http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf. Accessed 19 Feb. 2018.
10. Mulcahy A, Predmore Z, Soeren M. The cost savings potential of biosimilar drugs in the United States. 2014. https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdf. Accessed 19 Feb. 2018.
11. Crespi-Lofton J, Skelton JB. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference. J Am Pharm Assoc (2003). 2017;57:e15-27. https://doi.org/10.1016/j.japh.2017.05.014.
12. Derzi D, Ripp S, Ng C, Shoieb A, Finch G, Lorello L, et al. Comparative nonclinical assessments of the potential biosimilar PF-06410293 and adalimumab [abstract no. 276]. In: Society of Toxicology 53rd Annual Meeting and ToxExpo 2014; Phoenix, Arizona; 2014.
13. ClinicalTrials.gov. A study of PF-06410293 (adalimumab-Pfizer) and adalimumab (Humira) In healthy subjects (REFLECTIONS B538-07)) (B538-07). 2014 (last update: 13 April 2015). https://clinicaltrials.gov/ct2/show/NCT02237729. Accessed 19 Feb. 2018.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81. https://doi.org/10.1002/art.27584.
15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
16. Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. How much does disease activity score in 28 joints ESR and CRP calculations underestimate disease activity compared with the simplified disease activity index? Ann Rheum Dis. 2015;74:1132-7. https://doi.org/10.1136/annrheumdis-2013-204920.
17. Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol. 2007;10:9-16. https://doi.org/10.1111/j.1479-8077.2007.00248.x.
18. Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc. 2009;108:310-9. https://doi.org/10.1016/S0929-6646(09)60071-1.
19. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-26.
20. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16:658-73. https://doi.org/10.1208/s12248-014-9599-2.